Replies to post #3474 on $$$Ospreyeye: Charts, Technical Analysis & Japanes

[CPAP]

Thank you kindly. Looks like lots of great places for me to get started! Started reading what I could last night after I made my post but was looking for a good book. Thanks friend.

[~ Blue ~]

board and mods marked

[hawkshaw812]

thanks osprey you are a great asset to this board

[Chappy86]

Sorry for interrupting ...thanks for all the useful information.

[downinthewell]

Thanks for the chart analysis resources. You can bet I will check them out.

I've been a frequent trader spanning 2 plus years and only recently grasped the paramount role chart analysis plays in investment decisions.

.....been using "Stock Consultant" on Nasdaq.com occasionally

but recently discovered stocksta.com, a free service utilizing multiple analysis tools. But I'm a novice and can't really interpret and utilize the data analysis they provide

Today was interesting.....DIRV knocked right on the resistance at .0187. What I don't know is the strength of the resistance???

Tried to unload my 7.5M shares today at .0186, but only got a partial fill of 37K. Some would say that was "meant to be." :))))) Hold don't fold!!

Can I entice you to share your thoughts on what you foresee over the next couple of days?? More specifically tomorrow???

Many thanx in advance......Tidalgal

[the penny lover]

hi, what do you think off USTC. what would be good exit and buy targets to USTC

[stock1ace1]

RNWR @.60 no debt 20mill sharebuyback news out this week also news out today!!!!! Hidden gem folks otcqx !!!

[Shark Attack]

$ATTBF REVING UP!

[tiller]

A great post.
I am taking your advice.
It can't hurt.
GLTA

[mick]

good morning/ high five '$$$Ospreyeye: Charts, Technical Analysis & Japanese Candlestick Patterns$$$'

[mick]

interesting teaching all should read/\

Technical Analysis Guide Book Slide Show:........I think you'll find the information helpful..........

I was taught technical analysis by a former Marke Maker in an Educational group......we would have daily online conferences after the market closed........was a life changing experience!.......

Just trying to return the favor on this board..........checkout "The Master Swing Trader" by Alan S. Farley.....Lots of good info.....

Take a look at Stockcharts.com Chart School......this is a great place to start.....I highly recommend getting a Stockcharts.com membership.......it's worth it......

& ask lots of questions......nothing like experience to teach you how the Indicators react to share price movement.......

Start out w/ a few Indicators you see posted often.......learn an Indicator or two a day.......everyday add another tool to the belt......eventually you'll be a Master Chartist...

You're already a biostatistician.......technical analysis should come easy......just takes practice......if you have any questions please don't hesitate to ask............$$$

http://stockcharts.com/school/doku.php?id=chart_school

http://www.slideshare.net/BigTrends/the-technical-analysis-guidebook

[mick]

on your charting/ your 3 yr chart is fantastic read/ 4ma 8ma can you add 200ma to it for viewing

to rcha chart

to fb chart

to paas chart

[mick]

high five '$$$Ospreyeye: Charts, Technical Analysis & Japanese Candlestick Patterns$$$'

i had some time late last night/

i sawer quite ah few in death cross

[Long-vestor]

Of the most simple, basic indicators of sentiment and evaluating the potential future of a stock is the simple moving average.

Older than 100 years and these days discounted for the age as other technical indicators are adding into the various profiles.

Yet today the simple moving averages are enhanced with the automatic arteriogram rhythms in live charts.

The basic 5, 10, 20, 50, 100, 200 simple moving averages layout inside of a chart at any time increment automatically plot out intersections where price movement is most likely to occur.

The golden cross, a positive signal when the 200 day moving average moves into the positive side of the 50, below it. silver, 100 below the 50, can be foreseen ahead of time which is when the opportunity is availed. Such as, people will tout and scream that a stock has undergone a golden cross which signals buy. But, actually that's the too late, sorry Charlie timing. It does signal strength in a security, relative safety, but, that's for longer term opportunities. Short term opportunities are availed in anticipating its crossing, buying the lows ahead of it..

first the faster averages begin climbing above the 50, when the 20 goes above and if both, the 100 and 200 are near, with a high tilted downward angle the odds of gaining the cross increases tremendously. Or visa versa, faster averages are attacking the slower at a high tilt.

Catching the silver then golden inside of stinkies can reap doubles triples 10-20 baggers in no time at all.. Grabbing them prior to crossings inside of real companies can lead to real investment opportunities lasting for years.

live charting in 1, 5 and 15 minute time frames the SMA's will make crosses up down and sideways.

When you have the SMA's inside of your tool package, along with candles, MACD, Scholastics, and few other common studies, knowledge of patterns, unidirectional trend lines and a comprehensive understanding of fundamental analysis.. your crystal ball will shine brighter than some dope who's wishing, begging off of others, or buying the hype of a pumper/basher.

To play the future, you have to have the equipment to enable you to see it.

[mick]

da big slider/\ great reading/\
gett'in smart pills tonight/\

weekend golf

http://golfmanna.com/Pages/Article.aspx?Id=160

[mick]

me ah again/ high five '$$$Ospreyeye: Charts, Technical Analysis & Japanese Candlestick Patterns$$$'

[mick]

good evening/ $$$Ospreyeye: Charts, Technical Analysis & Japanese Candlestick Patterns$$$'

[mick]

aapl replaces at&t in dow 30/ early bird gets da worm?

[mick]

eyes on tza
you have symbol?

eyes
bonic eye company for blind people/\
i.p.o.'d $20 fell to $8 in recovery now

[mick]

it is friday, T.G.I.F. 04-10-2015

[mick]

i am watching sunday morning cbs ... good sunday morning all
on '$$$Ospreyeye: Charts, Technical Analysis & Japanese Candlestick Patterns$$$'

[mick]

good morning, early riser this morning. arwr pre-market winner.

$9.37 up over one dollar.

[mick]

good morning, topshelf.

re;
Technical Analysis Guide Book Slide Show:........I think you'll find the information helpful..........

I was taught technical analysis by a former Marke Maker in an Educational group......we would have daily online conferences after the market closed........was a life changing experience!.......

Just trying to return the favor on this board..........checkout "The Master Swing Trader" by Alan S. Farley.....Lots of good info.....

Take a look at Stockcharts.com Chart School......this is a great place to start.....I highly recommend getting a Stockcharts.com membership.......it's worth it......

& ask lots of questions......nothing like experience to teach you how the Indicators react to share price movement.......

Start out w/ a few Indicators you see posted often.......learn an Indicator or two a day.......everyday add another tool to the belt......eventually you'll be a Master Chartist...

You're already a biostatistician.......technical analysis should come easy......just takes practice......if you have any questions please don't hesitate to ask............$$$

http://stockcharts.com/school/doku.php?id=chart_school

http://www.slideshare.net/BigTrends/the-technical-analysis-guidebook

Learn to read Charts & Technical Analysis.....all are welcome....post your own charts & T/A & join the discussion
http://investorshub.advfn.com/$$$Ospreyeye-Charts-Technical-Analysis-&-Japanese-Candlestick-Patterns$$$-26060/

[mick]

wow on on this one big hitter /////\\\\\ PTBI

[mick]

good morning all/\ just getting on. whatzzz i missed ?????

[mick]

good morning, just gett'in on. ihub slow this morning.

[mick]

ALL /////\\\\\ WHAT DAY IS TODAY ????? 05-20-2015

[mick]

considering this is may,2015 trading otcbb have been exciting this month.

[mick]

hi my friend good morning. just getting on. did i miss da big one for today ?

[mick]

2/3's of longwkend gone. i am enjoying nice weather here in yuma,az.

other spots have wind rain and big flooding with some tornado stuff.

[mick]

Memorial Day and I see this/\America had "no will" to fight the extremists BY Iranian general /////\\\\\
ANSWER;
IRAN WANTS NUCLEAR BOMB --- ISRAEL KNOWSI T /////\\\\\
http://news.myway.com/index/id/top%7Cap.html
Iraq, Iran push back on US defense chief over Ramadi loss photo
BAGHDAD (AP) — Iraq and Iran pushed back Monday against

U.S. Defense Secretary Ash Carter's criticisms over the fall of Ramadi to the Islamic State group,

with an Iranian general going as far as saying America had "no will" to fight the extremists. In Baghdad, a spokesman to Iraq's prime...

answers/\

AMERICAN SOLDIERS DON'T LAY DOWN THEIR ARMS AND RUN/////\\\\\

[mick]

good morning, hope ya had happy long wkend

[mick]

good evening, been gone most of da day.

from doctor's lunch casino just dat ordinary driving traffic.

[mick]

good morning hard worker, '$$$Ospreyeye: Charts, Technical Analysis & Japanese Candlestick Patterns$$$'

[mick]

good morning, T.G.I.F.

[mick]

hi my friend, good evening. could flourish some/\ gbgm

[mick]

good morning, '$$$Ospreyeye: Charts, Technical Analysis & Japanese Candlestick Patterns$$$'

[mick]

i see this one going at 100% move/ ROYL

[mick]

good morning, i hope having ah great wkend.

[mick]

hi my friend, good morning.

radar gbgm

toxic debt ridden out.

[mick]

good evening, over over over, new i.p.o. FIT

[mick]

good morning, all on '$$$Ospreyeye: Charts, Technical Analysis & Japanese Candlestick Patterns$$$'

[mick]

hi my friend, good aftenoon.

back from laughin,nv.

had five days of comps.

[mick]

good morning, looks good going into 4th july wk.

[mick]

good morning and all on $$$Ospreyeye: Charts, Technical Analysis & Japanese Candlestick Patterns$$$'

[mick]

hi my friend, anything for PMCB ?????

[mick]

good morning, happy 4th july to all.

[mick]

me again, little side chat/\ it did not take long for Obama regime to clamp DONALD TRUMP/\

all of the business hitting D.T. are the clan Obama formed
in campaigning since beginning.

[mick]

good morning, stars and stripes forever.

[mick]

just got back from two day leave.

[mick]

[mick]

hi my friend wkend maintence ????? gearing for rest of july,2015 ?????

[mick]

good morning, did some chart on hcti on da wkend/


said ppo down adx up.

this is today so far/\

Hybrid Coating Technologies, Inc. (HCTI) 812% 211 HCTI 0.0085 0.0042 97.67% 9,318,550

[mick]

good morning, and to '$$$Ospreyeye: Charts, Technical Analysis & Japanese Candlestick Patterns$$$'

[mick]

good evening, just getting on.

problem sitting back is acting up.

[mick]

good morning, as oil goes $gold goes /////\\\\\

[mick]

hi my friend, just getting on. i was on earlier/\ good evening

[mick]

good morning. nice early morning sun here in yuma,az. very calm morning.

[mick]

good afternoon, '$$$Ospreyeye: Charts, Technical Analysis & Japanese Candlestick Patterns$$$'

[mick]

good morning, hope you are having nice wkend, as i am.

[mick]

good morning, $$$Ospreyeye: Charts, Technical Analysis & Japanese Candlestick Patterns$$$'

[mick]

good morning/ all looks good this wk. short on aapl so far $125

[The Night Stalker]

PWDY

[mick]

good morning, happy wkend/ $$$Ospreyeye: Charts, Technical Analysis & Japanese Candlestick Patterns$$$'

[mick]

good morning, '$$$Ospreyeye: Charts, Technical Analysis & Japanese Candlestick Patterns$$$'

[The Night Stalker]

PWDY

[mick]

thank you, safe and back this evening. good evening

[mick]

good morning, '$$$Ospreyeye: Charts, Technical Analysis & Japanese Candlestick Patterns$$$'

[mick]

good morning, $$$Ospreyeye: Charts, Technical Analysis & Japanese Candlestick Patterns$$$'

[mick]

good morning but not fer markets unless short.

i called 07-09-2015 bear.

[mick]

good morning . '$$$Ospreyeye: Charts, Technical Analysis & Japanese Candlestick Patterns$$$'

[mick]

thank you, good morning.

[mick]

good morning, step by step /////\\\\\ walking through ah maze /////\\\\\

[mick]

good morning my friend,

[mick]

good morning all. 08-29-2015

[mick]

off topic/ interesting Pope vs our Congress ????? to address our congress soon.

were is our congress on dis matter ?????

like trump said

our congress ?????

my word is internal conspiracy /////\\\\\

[mick]

good afternoon, 08-30-2015

[mick]

good morning, lot of chat

on

SIRG

mou still pending.

no news or pr release to shareholders.

[mick]

good morning, trader's not willing to stay the market over weekend.

SHANGHI DRAGGING JAPAN INTO TURMOIL /////\\\\\

[mick]

happy labor day to all.

[mick]

good morning/ as you know me some, i am reading excerpt/ BABA can fall another 50%

i think jack ma said company first before shareholders.

since baba public hit $120 plus bot recent pps $60 plus.

[mick]

since beginning june,2015 otcbb been active.

[mick]

good morning, just getting on.

[mick]

good morning, 09-19-2015

[mick]

good morning all. 10-05-15

[mick]

good evening all on '$$$Ospreyeye: Charts, Technical Analysis & Japanese Candlestick Patterns$$$'

[mick]

good morning all on '$$$Ospreyeye: Charts, Technical Analysis & Japanese Candlestick Patterns$$$'

[mick]

good morning, 10-11-15.

[mick]

good evening, '$$$Ospreyeye: Charts, Technical Analysis & Japanese Candlestick Patterns$$$'

[mick]

good morning, '$$$Ospreyeye: Charts, Technical Analysis & Japanese Candlestick Patterns$$$'

[mick]

good morning, all on '$$$Ospreyeye: Charts, Technical Analysis & Japanese Candlestick Patterns$$$'

how is your wkend ?????

[stock1ace1]

CEGX ~ @.0091 ( Lawsuit Victory ) 8k Released 11/25/15

[mick]

good afternoon, two robotic companies. EKSO RWLK

[beach_trades]

$FREE looks ready for bounce

[BottomBounce]

$CUBA Golden Cross

[mick]

good afternoon my friend/ happy june to ya

[BottomBounce]

$AMRS do you think this will hit a buck anytime soon?

[mick]

hi my friend, good morning/ hope all is good.

[~ Blue ~]

PVCT loading zone for me at .105

[$Pistol Pete$]

$PMCB Technical Analysis....long term "STRONG HOLD"

1. Resistance 1: $0.0900
2. Resistance2: $0.1051

http://allotcbb.com/quote.php?symbol=pmcb

[$Pistol Pete$]

$PMCB Summary Of The Resistance On PMCB

A. Resistance 1: $0.1595

B. Resistance 2: $0.1863

[BottomBounce]

$ASTI Setting up Bull Run Technical Chart >

[$Pistol Pete$]

$MFST Americanbulls trigger "BUY" and "STAY LONG" MFST

https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=MFST

[$Pistol Pete$]

$PMCB Americanbulls Trigger "BUY" on Jan 30 2017 PMCB

https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=PMCB



Go $PMCB

[~ Blue ~]

IFON 15% up. CEO holds 30.28% of shares. Outstanding shares 14.3 million. NO DEBT!

[~ Blue ~]

IFON is skyrocketing!!

[~ Blue ~]

Sold CYTR at .85 loaded IMUC for next week

[~ Blue ~]

$SEEK~.0002~ 100% up. great 873 Million volume
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=136924191

[$Pistol Pete$]

$DFFN Diffusion Pharmaceuticals Announces First Patient Dosed in Phase 3 Trial with TSC in Inoperable Glioblastoma Multiforme DFFN



https://www.marketwatch.com/story/diffusion-pharmaceuticals-announces-first-patient-dosed-in-phase-3-trial-with-tsc-in-inoperable-glioblastoma-multiforme-2018-01-29

CHARLOTTESVILLE, Va., Jan 29, 2018 (GLOBE NEWSWIRE via COMTEX) --

Diffusion Pharmaceuticals Inc. DFFN, +6.53% ("Diffusion" or "the Company"), a clinical-stage biotechnology company focused on extending the life expectancy of cancer patients, today announced that the first patient has been dosed in the Company's Phase 3 clinical trial with trans sodium crocetinate ("TSC") in patients with newly-diagnosed inoperable glioblastoma multiforme ("GBM"), a type of brain cancer. The INTACT (INvestigating Tsc Against Cancerous Tumors) trial will compare standard of care ("SOC") radiation therapy ("RT") and chemotherapy plus TSC against SOC alone.
"We are pleased to be dosing patients so soon following the opening of the INTACT trial just a few weeks ago," said David Kalergis, Chief Executive Officer of Diffusion Pharmaceuticals. "We believe that this Phase 3 study will offer new hope for inoperable GBM patients who are administered TSC along with their standard therapies."

The INTACT Phase 3 study follows a previous Phase 2 GBM study in which the inoperable patient subgroup showed a nearly four-fold increase in survival compared with historical controls when TSC was added to their treatment regimen (40.0% alive at two years vs. 10.4%). TSC's unique mechanism of action affects the tumor micro-environment, making treatment-resistant cancer cells more susceptible to the tumor-killing power of conventional RT and chemotherapy (temozolomide) by re-oxygenating the hypoxic portion of the tumor. The Company believes that a largely intact GBM tumor vasculature with limited surgical resection is conducive to TSC's tumor re-oxygenation properties, and that this contributed to the survival increase in the Phase 2 GBM inoperable patient subgroup.

The trial will screen 300 patients and enroll 264 with the expectation that results from 236 patients will be available for analysis. Enrolled patients will be randomized in a 1:1 ratio into treatment and control groups. Patients in the treatment group will receive SOC temozolomide and RT plus an intravenous bolus of TSC administered shortly before their SOC treatments. Patients in the control group will receive SOC alone. The study will compare overall survival at two years between patients in the two groups. Up to 100 clinical sites in the U.S. and Europe are expected to participate.

About the GBM Phase 3 INTACT Trial

The INTACT clinical trial is an open-label, randomized, controlled, Phase 3 safety and efficacy registration trial. Subjects will be randomized at baseline to SOC for first-line treatment of GBM plus TSC, or to SOC alone. The SOC for GBM is temozolomide plus RT for 6 weeks followed by 28 days of rest, followed by 6 cycles of post-radiation temozolomide treatment.

For patients randomized to the TSC group, TSC will be administered during both the RT and post-radiation temozolomide treatment periods.

During the RT treatment period subjects will receive:

Focal RT delivered as 60Gy/30 fractions scheduled at 2Gy/day for 5 days each week (Monday through Friday) for 6 weeks.
Temozolomide 75 mg/m [2 ] orally once daily (usually administered the night preceding each RT session) starting the evening before the first RT session over a period of 42 calendar days with a maximum of 49 days.
TSC 0.25 mg/kg IV for 3 days each week (e.g., Monday, Wednesday, Friday, or other schedule that supplies a minimum 3 TSC doses per week) administered between 45 to 60 minutes prior to each RT session.
During the 28-day rest period all subjects will receive no treatment.

During the post-radiation 6-cycle temozolomide treatment period:

All subjects will receive 28-day oral temozolomide (150 mg/m [2] first cycle and 200 mg/m [2] all subsequent cycles as tolerated) administered on Day 1-5 (Monday through Friday) of each 28-day cycle.
Controls will receive oral temozolomide at night at home per the SOC and are not required to attend clinic visits during this period.
Subjects randomized to TSC will receive TSC 1.5 mg/kg (or another dose if recommended by the Data Safety Monitoring Board ("DSMB") 1.5 to 2 hours before their temozolomide dose during the daytime for 3 days during the first week of each 28-day cycle (Days 1, 3, and 5; e.g., Monday, Wednesday, Friday or other schedule that supplies at minimum 3 TSC doses per week). The Tuesday, Thursday doses will be given at night at home. Long-acting antiemetics may be administered prior to daytime temozolomide dosing on Days 1, 3, 5.
The safety, tolerability and pharmacokinetics ("PK") of TSC at higher doses than 0.25 mg/kg with temozolomide will be assessed during adjuvant therapy. TSC at doses between 0.25 mg/kg and up to 1.5 mg/kg in combination with concomitant temozolomide will be assigned (not randomized) in the first 8 subjects enrolled in the INTACT trial. These patients will undergo RT plus temozolomide plus TSC treatment (0.25 mg/kg) for 6 weekly cycles followed by 4 weeks of rest in standard fashion. At the Week 10 clinic visit the same 8 subjects will be assigned to treatment, with 2 subjects each assigned to TSC at doses of 0.25, 0.50, 1.0, and 1.5 mg/kg. These subjects will be studied in parallel for 2 28-day cycles with inclusion of appropriate blood sampling collection for TSC and temozolomide PK. The DSMB will examine the resultant safety data after 2 cycles (Weeks 11 through 18 of post-radiation temozolomide treatment period; Days 1 to 56). The DSMB may recommend continued use of the 1.5 mg/kg TSC dose for the post-radiation temozolomide treatment period, or may prescribe another dose based on their observations. Subjects then entering into the INTACT trial will be randomized at baseline between TSC plus SOC, or SOC alone.

Further details about the trial protocol are available at www.clinicaltrials.gov.

The baseline assessment for determining progression-free survival overall response rate and to rule out pseudo-progression will be at 10 weeks via MRI using the modified Response Assessment in Neuro-Oncology scale. The hazard ratio for the trial will be 0.67, which corresponds to 22% two-year survival in the TSC arm, the lower limit of the 95% confidence interval for the biopsy-only subjects in Diffusion's Phase 2 trial, and 10% survival in the SOC arm. The estimated median survival is therefore 10 months for the SOC arm vs. 14.9 months for the TSC plus SOC arm. In order to achieve 80% power, the trial requires 118 subjects in each arm.

The study will achieve the designed 80% statistical power at 198 events, where an event is defined as death. The first analysis will occur at the earlier of two years follow-up for all subjects or 198 events. If the first analysis is at 198 events, the analysis will be a standard 2-sided stratified log-rank test at the ?'?=0.05 significance level. If the first analysis is at two years, the Company will perform the analysis using the O'Brien-Fleming Method.

About Treatment-Resistant Cancers and TSC

Oxygen deprivation at the cellular level (hypoxia) is the result of rapid tumor growth, causing the tumor to outgrow its blood supply. Cancerous tumor cells thrive with hypoxia and the resultant changes in the tumor microenvironment cause the tumor to become resistant to RT and chemotherapy. Using a novel, proprietary mechanism of action, Diffusion's lead drug TSC appears to counteract tumor hypoxia - and therefore treatment resistance - by safely re-oxygenating tumor tissue, thus enhancing tumor kill and potentially prolonging patient life expectancy. Oxygen levels of normal tissue appear to remain unaffected upon administration of TSC.

About Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on improving patient outcomes in unmet medical needs using its novel small molecule trans sodium crocetinate (TSC). Diffusion is developing TSC for use in conditions where hypoxia (oxygen deprivation) is known to diminish the effectiveness of SOC treatments. In oncology, TSC targets the cancer's hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancer cells more vulnerable to the therapeutic effects of SOC treatments without the apparent occurrence of any serious side effects. In non-oncology indications, therapeutic benefit would be achieved directly through re-oxygenation of the tissue threatened with cell death from hypoxia.

A Phase 3 randomized, controlled registration trial with TSC and SOC chemotherapy and radiation, compared with SOC alone in 236 patients newly diagnosed with inoperable glioblastoma multiforme (GBM), a type of brain cancer, is underway. A Phase 2 clinical program was completed in the second quarter of 2015 and evaluated 59 patients with newly diagnosed GBM. This open-label, historically controlled study demonstrated a favorable safety and efficacy profile for TSC combined with SOC, including a 37% improvement in overall survival compared with the control group at two years. A particularly strong efficacy signal was seen in the subset of inoperable patients where survival of TSC-treated patients at two years was nearly four-fold higher compared with the controls. Due to its novel mechanism of action, TSC has safely re-oxygenated a range of tumor types in preclinical and clinical studies. Diffusion believes the therapeutic potential of TSC is not limited to specific tumors, thereby making it potentially useful to improve SOC treatments of other life-threatening cancers. Additional studies under consideration include Phase 2 trials in pancreatic cancer and brain metastases, with study initiation subject to receipt of additional funding or collaborative partnering. The Company also believes that TSC has potential application in other indications involving hypoxiaincluding stroke, where the Company recently announced its PHAST-TSC study which will be conducted in co-operation with the University of California Los Angeles (UCLA) and the University of Virginia (UVA) to test TSC in stroke patients in an in-ambulance clinical trial setting.

Forward-Looking Statements

To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the company's plans, objectives, expectations and intentions with respect to future operations and products, the potential of the company's technology and product candidates, the anticipated timing of future clinical trials and protocol review, and other statements that are not historical in nature, particularly those that utilize terminology such as "would," "will," "plans," "possibility," "potential," "future," "expects," "anticipates," "believes," "intends," "continue," "expects," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause the company's actual results to be materially different than those expressed in or implied by such forward-looking statements. Particular uncertainties and risks include: general business and economic conditions; the company's need for and ability to obtain additional financing; and the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance, and the various risk factors (many of which are beyond Diffusion's control) as described under the heading "Risk Factors" in Diffusion's filings with the United States Securities and Exchange Commission. All forward-looking statements in this news release speak only as of the date of this news release and are based on management's current beliefs and expectations. Diffusion undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts:
David Kalergis, CEO
Diffusion Pharmaceuticals Inc.
[phone]
[e-mail]
or
LHA Investor Relations
Kim Sutton Golodetz
[phone]
[e-mail]

Copyright (C) 2018 GlobeNewswire, Inc. All rights reserved.

[PENNIEStoSTACKS]

O can you give me opinion on this chart

[VEGAS BABY]

Sounds great buddy, I will absolutely check it out. Very Cool. Later.

[$Pistol Pete$]

$MNKD MannKind Corporation saw 11.28 million shares of its stock trade hands, that's out of 145.34 million shares outstand. The stock has an average daily volume of 2.19 million shares. After hitting a new 52-week low, MannKind Corporation enters the new trading day with a market cap of 167.14 million, a 50-day SMA of $1.80 and a 200-day SMA of $2.41